Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis

Internal Medicine

Volumn 44, Issue 5, 2005, Pages 428-433

  Matsuda, Masayuki ^a   Yamada, Toshiyuki ^b   Gono, Takahisa ^a   Shimojima, Yasuhiro ^a   Ishii, Wataru ^a   Fushimi, Tomohisa ^a   Sakashita, Kazuo ^a   Koike, Kenichi ^a   Ikeda, Shu Ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AL amyloidosis; Autologous peripheral blood stem cell transplantation; Free light chain; High dose melphalan; Immunofixation; M protein; VAD

Indexed keywords

AMYLOID; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN LIGHT CHAIN; M PROTEIN; MELPHALAN; VINCRISTINE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREACTIVITY; JAPAN; MALE; MULTIPLE MYELOMA; NEPHELOMETRY; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN URINE LEVEL; QUANTITATIVE ANALYSIS;

ADULT; AGED; AMYLOIDOSIS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BIOPSY; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; INCIDENCE; INFUSIONS, INTRAVENOUS; INTESTINAL MUCOSA; JAPAN; KIDNEY; MALE; MELPHALAN; MIDDLE AGED; MYELOMA PROTEINS; NEPHELOMETRY AND TURBIDIMETRY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE;

EID: 21244490045     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.44.428     Document Type: Article

References (13)

1. Buxbaum J. The amyloidoses. in: Rheumatology. 2nd ed. Klippel JH, Dieppe PA, Eds. Mosby, London, 1998: 8.27.1-10.
2. Kyle RA, Gertz MA. Primary systemic amyloidosis. Clinical and laboratory features in 474 cases. Semin Hematol 32: 45-59, 1995.
3. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 97: 2900-2902, 2001.
4. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47: 673-680, 2001.
5. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48: 1437-1444, 2002.
6. Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 119: 274-278, 2003.
7. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122: 78-84, 2003.
8. Hoshii Y, Setoguchi M, Iwata T, et al. Useful polyclonal antibodies against synthetic peptides corresponding to immunoglobulin light chain constant region for immunohistochemical detection of immunoglobulin light chain amyloidosis. Pathol Int 51: 264-270, 2001.
9. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121: 749-757, 2003.
10. Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL amyloidosis: survival and responses in 25 patients. Blood 91: 3662-3670, 1998.
11. Gono T, Matsuda M, Shimojima Y, et al. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese criteria for patient selection and our experiences. Amyloid: J Protein Folding Disord 11: 245-256, 2004.
12. Gono T, Matsuda M, Dohi N, et al. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med 42: 72-77, 2003.
13. Clark RJ, Katzmann JA, Abraham RS, Lymph JF, Kyle RA, Bradwell AR. Detection of monoclonal free light chains by nephelometry: normal ranges and relative sensitivity. Clin Chem 47: a27, 2001.